Incyte Corporation (INCY)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 51.65 |
| Open | 51.65 |
| Bid | 51.68 x 100 |
| Ask | 51.82 x 200 |
| Day's range | 51.14 - 51.83 |
| 52-week range | 50.27 - 75.74 |
| Volume | |
| Avg. volume | 1,756,574 |
| Market cap | 11.617B |
| Beta (5Y monthly) | 0.67 |
| PE ratio (TTM) | 19.52 |
| EPS (TTM) | 2.65 |
| Earnings date | 30 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 74.29 |
ZacksAllogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?
Allogene Therapeutics (ALLO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksIncyte (INCY) Earnings Expected to Grow: Should You Buy?
Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksIncyte (INCY) to Report Q1 Earnings: What's in the Cards?
Incyte's (INCY) first-quarter 2024 revenues are likely to have been driven by the U.S. sales and royalties from Novartis on ex-U.S. sales of its lead drug, Jakafi.
© 2024 Yahoo. All rights reserved.